
Landmark Approval: Datopotamab Deruxtecan Approval in China, Signaling a Major Shift in Breast Cancer Treatment Landscape
China’s breast cancer treatment landscape has reached a new milestone with the regulatory approval of the globally innovative antibody–drug conjugate Datopotamab Deruxtecan (Datroway). Official Approval:





















